At a glance
ClinicalIndex Comparison RecordN/ACompleted· 100 enrolled
Drug / intervention
68Ga-Pentixafor PET/CT imagingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study
In Brief
An observational study evaluating 68Ga-Pentixafor PET/CT imaging for Primary Aldosteronism. Completed, enrolled 100 participants across 1 site.
Detailed Summary
To evaluate the value of 68Ga-Pentixafor PET/CT in the diagnosis of primary aldosteronism subtype
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Aldosteronism
CountriesChina
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedNov 2021
Primary CompletionMay 2022
Study CompletionMay 2022
TodayJul 2026
First PostedNov 23, 2021
Enrollment StartNov 11, 2021
Primary CompletionMay 1, 2022
Study CompletionMay 31, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.6 years ago
Interventions
68Ga-Pentixafor PET/CT imagingother
68Ga-Pentixafor PET/CT imaging